Research affiliation
Ky Lab, Perelman School of Medicine; postdoctoral and clinical fellows section[7]
Journey
Education, training and research through time.
Combined degree
University of Minnesota
Residency
University of Pennsylvania
Fellowship
University of Pennsylvania
- Enrolled beginning Jul 2016; completion endpoint unknownCombined degreeMinneapolis, Minnesota
MD-PhD program[2][3][6][9]
The self-reported ORCID entry identifies one University of Minnesota MD-PhD program beginning in July 2016. The dissertation record supplies a June 2022 PhD completion point, and Minnesota's 2024 match list supplies a later residency-match observation. The stale ORCID 'present' endpoint is not used as a completion date.
- Jun 2022·Completed PhD dissertation in Molecular, Cellular, Developmental Biology and Genetics[2]
- 2024 match·Matched to Penn Internal Medicine Physician Scientist Training Program[9]
2020 to 2023
ResearchMinneapolis, MinnesotaNIH/NHLBI F30 research fellowship[8]
University of Minnesota
Minnesota lists Sierra-Pagán's NHLBI F30 award, HL152561, for work on mechanisms governing vasculogenesis.
- 2017
1 attributed work
- 2019
- 2020
1 attributed work
- ETV2-Rhoj Cascade Regulates Endothelial Progenitor Cell Migration During Embryogenesis
Arterioscler Thromb Vasc Biol
- ETV2-Rhoj Cascade Regulates Endothelial Progenitor Cell Migration During Embryogenesis
- 2021
1 attributed work
- Angiotensin II Induces Differentiation of Human Neuroblastoma Cells by Increasing MAP2 and ROS Levels
J Renin Angiotensin Aldosterone Syst
- Angiotensin II Induces Differentiation of Human Neuroblastoma Cells by Increasing MAP2 and ROS Levels
- 2022
2 attributed works
- The regulatory role of pioneer factors during cardiovascular lineage specification: A mini review
Front Cardiovasc Med · First author
- ETV2 functions as a pioneer factor to regulate and reprogram the endothelial lineage
Nat Cell Biol
- The regulatory role of pioneer factors during cardiovascular lineage specification: A mini review
- 2023
1 attributed work
- FOXK1 regulates Wnt signalling to promote cardiogenesis
Cardiovasc Res · First author
- FOXK1 regulates Wnt signalling to promote cardiogenesis
- 2024
- 2025
3 attributed works
- The pioneer factor, ETV2, regulates networks to specify the embryonic endothelial lineage
Cardiovasc Res
- Congenital heart disease-related mortality during the first year of life: The Peruvian experience
Int J Cardiol Congenit Heart Dis
- MYCN Regulates Cardiomyocyte Proliferation, Metabolism, and Regeneration in the Mammalian Heart
Circulation
- The pioneer factor, ETV2, regulates networks to specify the embryonic endothelial lineage
- Observed on current roster, Sep 4, 2026FellowshipPhiladelphia, Pennsylvania
First-year Cardiovascular Disease Fellow[3]
Penn's roster places Sierra-Pagan among first-year cardiovascular disease fellows. This observation does not establish the fellowship's full interval.
Observed Sep 4, 2026
ResearchPhiladelphia, PennsylvaniaKy Lab clinical-fellow research affiliation[7]
Ky Lab, Perelman School of Medicine
The Ky Lab lists Sierra Pagan in its postdoctoral and clinical fellows section and specifically calls him a cardiovascular disease fellow. It does not establish a postdoctoral appointment or start date.
- 2026
1 attributed work
- Cardiovascular Risk Prediction in Breast Cancer Survivors: Are Polygenic Scores Ready for Prime Time?
JACC CardioOncol · First author
- Cardiovascular Risk Prediction in Breast Cancer Survivors: Are Polygenic Scores Ready for Prime Time?
- Matched in 2024; attendance dates unknownResidencyPhiladelphia, Pennsylvania
Internal Medicine Physician Scientist Training Program[3][9]
Minnesota's 2024 match list names Penn Internal Medicine PSTP, and Penn later names its own hospital as Sierra-Pagan's residency institution. The match year is a point observation, not a residency start date.
Works appear by publication year. Their position does not establish where or when the underlying research was performed.
Education and training
Degrees, training periods and the milestones within them.
- Enrolled beginning Jul 2016; completion endpoint unknownCombined degreeMinneapolis, Minnesota
MD-PhD program[2][3][6][9]
The self-reported ORCID entry identifies one University of Minnesota MD-PhD program beginning in July 2016. The dissertation record supplies a June 2022 PhD completion point, and Minnesota's 2024 match list supplies a later residency-match observation. The stale ORCID 'present' endpoint is not used as a completion date.
- Jun 2022·Completed PhD dissertation in Molecular, Cellular, Developmental Biology and Genetics[2]
- 2024 match·Matched to Penn Internal Medicine Physician Scientist Training Program[9]
2020 to 2023
ResearchMinneapolis, MinnesotaNIH/NHLBI F30 research fellowship[8]
University of Minnesota
Minnesota lists Sierra-Pagán's NHLBI F30 award, HL152561, for work on mechanisms governing vasculogenesis.
- Matched in 2024; attendance dates unknownResidencyPhiladelphia, Pennsylvania
Internal Medicine Physician Scientist Training Program[3][9]
Minnesota's 2024 match list names Penn Internal Medicine PSTP, and Penn later names its own hospital as Sierra-Pagan's residency institution. The match year is a point observation, not a residency start date.
- Observed on current roster, Sep 4, 2026FellowshipPhiladelphia, Pennsylvania
First-year Cardiovascular Disease Fellow[3]
Penn's roster places Sierra-Pagan among first-year cardiovascular disease fellows. This observation does not establish the fellowship's full interval.
Observed Sep 4, 2026
ResearchPhiladelphia, PennsylvaniaKy Lab clinical-fellow research affiliation[7]
Ky Lab, Perelman School of Medicine
The Ky Lab lists Sierra Pagan in its postdoctoral and clinical fellows section and specifically calls him a cardiovascular disease fellow. It does not establish a postdoctoral appointment or start date.
Research
Research award
NIH/NHLBI F30 HL152561, Mechanisms that govern vasculogenesis[8]
2020 to 2023
Research topic
Epigenetic regulation of cardiovascular development, endothelial lineage specification, cardiac regeneration, ETV2, and FOXK1[2]
Through June 2022
Publications
13 attributed works · 3 first author. Counts reflect resolved authorship and may be incomplete.
- 2026Cardiovascular Risk Prediction in Breast Cancer Survivors: Are Polygenic Scores Ready for Prime Time?JACC CardioOncolfirst authorPMID 41705756
- 2025The pioneer factor, ETV2, regulates networks to specify the embryonic endothelial lineageCardiovasc ResPMID 40832854
- 2025Congenital heart disease-related mortality during the first year of life: The Peruvian experienceInt J Cardiol Congenit Heart DisPMID 40083608
- 2025MYCN Regulates Cardiomyocyte Proliferation, Metabolism, and Regeneration in the Mammalian HeartCirculationPMID 40892889
- 2023FOXK1 regulates Wnt signalling to promote cardiogenesisCardiovasc Resfirst authorPMID 37036809
- 2022The regulatory role of pioneer factors during cardiovascular lineage specification: A mini reviewFront Cardiovasc Medfirst authorPMID 36082116
- 2022ETV2 functions as a pioneer factor to regulate and reprogram the endothelial lineageNat Cell BiolPMID 35550615
- 2021Angiotensin II Induces Differentiation of Human Neuroblastoma Cells by Increasing MAP2 and ROS LevelsJ Renin Angiotensin Aldosterone SystPMID 34285710
- 2020ETV2-Rhoj Cascade Regulates Endothelial Progenitor Cell Migration During EmbryogenesisArterioscler Thromb Vasc BiolPMID 33115267
- 2019
- 2017
Sources
Sources are listed once and connected to each accepted claim they support. Excerpts preserve the source language used in the review.
- [1]PubMed records for Javier Sierra-Pagan author results (13 records)
13 source claims · Reviewed Sep 5, 2026
Attributed work: Angiotensin II Induces Differentiation of Human Neuroblastoma Cells by Increasing MAP2 and ROS Levels | DOI 10.1155/2021/6191417 | PMID 34285710
Jun 14, 2021
PMID 34285710 | Javier Sierra-Pagan
Attributed work: Cardiovascular Risk Prediction in Breast Cancer Survivors: Are Polygenic Scores Ready for Prime Time? | DOI 10.1016/j.jaccao.2025.12.001 | PMID 41705756
February 2026
PMID 41705756 | Javier Sierra-Pagan
Attributed work: Congenital heart disease-related mortality during the first year of life: The Peruvian experience | DOI 10.1016/j.ijcchd.2024.100557 | PMID 40083608
March 2025
PMID 40083608 | Javier Sierra-Pagan
Attributed work: ETV2 functions as a pioneer factor to regulate and reprogram the endothelial lineage | DOI 10.1038/s41556-022-00901-3 | PMID 35550615
May 2022
PMID 35550615 | Javier E Sierra-Pagan | ETV2 functions as a pioneer factor
Attributed work: ETV2-Rhoj Cascade Regulates Endothelial Progenitor Cell Migration During Embryogenesis | DOI 10.1161/ATVBAHA.120.314488 | PMID 33115267
December 2020
PMID 33115267 | Javier E Sierra-Pagan | ETV2-Rhoj Cascade
Attributed work: ETV2 transcriptionally activates Rig1 gene expression and promotes reprogramming of the endothelial lineage | DOI 10.1038/s41598-024-78115-w | PMID 39562637
Nov 19, 2024
PMID 39562637 | Javier E Sierra-Pagan
Attributed work: Etv2 transcriptionally regulates Yes1 and promotes cell proliferation during embryogenesis | DOI 10.1038/s41598-019-45841-5 | PMID 31278282
Jul 5, 2019
PMID 31278282 | Javier E Sierra-Pagan | Etv2 transcriptionally regulates Yes1
Attributed work: FOXK1 regulates Wnt signalling to promote cardiogenesis | DOI 10.1093/cvr/cvad054 | PMID 37036809
Jul 6, 2023
PMID 37036809 | Javier E Sierra-Pagan | FOXK1 regulates Wnt signalling to promote cardiogenesis
Attributed work: Genome-Nuclear Lamina Interactions Regulate Cardiac Stem Cell Lineage Restriction | DOI 10.1016/j.cell.2017.09.018 | PMID 29033129
Oct 19, 2017
PMID 29033129 | Javier E Sierra-Pagan | Genome-Nuclear Lamina Interactions Regulate Cardiac Stem Cell Lineage Restriction
Attributed work: MYCN Regulates Cardiomyocyte Proliferation, Metabolism, and Regeneration in the Mammalian Heart | DOI 10.1161/CIRCULATIONAHA.124.070930 | PMID 40892889
Sep 2, 2025
PMID 40892889 | Javier E Sierra-Pagan
Attributed work: Release of Soluble Insulin Receptor From Neurons by Cerebrospinal Fluid From Patients With Neurocognitive Dysfunction and HIV Infection | DOI 10.3389/fneur.2019.00285 | PMID 30972014
Mar 26, 2019
PMID 30972014 | Javier Sierra-Pagan
Attributed work: The pioneer factor, ETV2, regulates networks to specify the embryonic endothelial lineage | DOI 10.1093/cvr/cvaf127 | PMID 40832854
Oct 24, 2025
PMID 40832854 | Javier E Sierra-Pagan
Attributed work: The regulatory role of pioneer factors during cardiovascular lineage specification: A mini review | DOI 10.3389/fcvm.2022.972591 | PMID 36082116
Aug 23, 2022
PMID 36082116 | Javier Sierra-Pagan
- [2]University of Minnesota Digital Conservancy OAI record: Epigenetic regulatory mechanisms that govern cardiovascular development
3 source claims · 3 journey details · Reviewed Sep 5, 2026
MD-PhD program: Enrolled beginning Jul 2016; completion endpoint unknown. The self-reported ORCID entry identifies one University of Minnesota MD-PhD program beginning in July 2016. The dissertation record supplies a June 2022 PhD completion point, and Minnesota's 2024 match list supplies a later residency-match observation. The stale ORCID 'present' endpoint is not used as a completion date.
Completed PhD dissertation in Molecular, Cellular, Developmental Biology and Genetics: Jun 2022
Sierra-Pagan reports beginning an MD-PhD program at the University of Minnesota in July 2016. ORCID's old 'present' endpoint does not establish when the program ended, while Minnesota separately dates the PhD dissertation to June 2022 and the residency match to 2024.
Biographical context: PhD dissertation: Epigenetic regulatory mechanisms that govern cardiovascular development
June 2022
Epigenetic regulatory mechanisms that govern cardiovascular development | Sierra Pagan, Javier | University of Minnesota Ph.D. dissertation. 2022
Graduate education: University of Minnesota PhD, Molecular, Cellular, Developmental Biology and Genetics; advisor Daniel Garry
Through June 2022
University of Minnesota Ph.D. dissertation. 2022. Major: Molecular, Cellular, Developmental Biology and Genetics. Advisor: Daniel Garry.
Research topic: Epigenetic regulation of cardiovascular development, endothelial lineage specification, cardiac regeneration, ETV2, and FOXK1
Through June 2022
identified novel epigenetic regulatory mechanisms that govern cardiovascular development, particularly within the vascular and cardiac muscle lineages ... ETV2 ... FOXK1
- [3]Reviewed current trainee roster
2 source claims · 4 journey details · Reviewed Sep 5, 2026
MD-PhD program: Enrolled beginning Jul 2016; completion endpoint unknown. The self-reported ORCID entry identifies one University of Minnesota MD-PhD program beginning in July 2016. The dissertation record supplies a June 2022 PhD completion point, and Minnesota's 2024 match list supplies a later residency-match observation. The stale ORCID 'present' endpoint is not used as a completion date.
Internal Medicine Physician Scientist Training Program: Matched in 2024; attendance dates unknown. Minnesota's 2024 match list names Penn Internal Medicine PSTP, and Penn later names its own hospital as Sierra-Pagan's residency institution. The match year is a point observation, not a residency start date.
First-year Cardiovascular Disease Fellow: Observed on current roster, Sep 4, 2026. Penn's roster places Sierra-Pagan among first-year cardiovascular disease fellows. This observation does not establish the fellowship's full interval.
The available sources do not establish pre-medical education, the MD conferral date, or exact residency dates.
Fellowship: Cardiovascular Disease Fellowship, University of Pennsylvania
1st year fellows ... Javier Sierra-Pagan, MD, PhD
Medical school: University of Minnesota Medical School (MD)
Through 2024
Javier Sierra-Pagan, MD, PhD | Medical School: University of Minnesota Medical School
- [4]Javier Sierra-Pagan portrait from Penn CVI match announcement
1 source claim · Reviewed Sep 5, 2026
Official headshot: Portrait
Penn CVI figure aria-labelledby='javiersierra-pagan,md,phd-author-3-spotlight-48' contains this exact image and figcaption 'Javier Sierra-Pagan, MD, PhD' under the Penn cardiovascular fellowship match announcement.
- [5]OpenAlex author A5072603723 | Javier E. Sierra-Pagán
1 source claim · Reviewed Sep 5, 2026
Official profile: Official profile
display_name: Javier E. Sierra-Pagán; orcid: https://orcid.org/0000-0002-6155-4336; works_count: 26
- [6]ORCID record 0000-0002-6155-4336 | Javier Sierra-Pagan
1 source claim · 4 journey details · Reviewed Sep 5, 2026
MD-PhD program: Enrolled beginning Jul 2016; completion endpoint unknown. The self-reported ORCID entry identifies one University of Minnesota MD-PhD program beginning in July 2016. The dissertation record supplies a June 2022 PhD completion point, and Minnesota's 2024 match list supplies a later residency-match observation. The stale ORCID 'present' endpoint is not used as a completion date.
Sierra-Pagan reports beginning an MD-PhD program at the University of Minnesota in July 2016. ORCID's old 'present' endpoint does not establish when the program ended, while Minnesota separately dates the PhD dissertation to June 2022 and the residency match to 2024.
ORCID also lists undated American Heart Association membership and undated service with the International Society for Stem Cell Research, but provides no role titles or activity dates.
The available sources do not establish pre-medical education, the MD conferral date, or exact residency dates.
Official profile: Official profile
given-names: Javier; family-name: Sierra-Pagan; path: 0000-0002-6155-4336
- [7]Lab Members | The Ky Lab | Perelman School of Medicine
1 source claim · 1 journey details · Reviewed Sep 5, 2026
Ky Lab clinical-fellow research affiliation: Observed Sep 4, 2026. The Ky Lab lists Sierra Pagan in its postdoctoral and clinical fellows section and specifically calls him a cardiovascular disease fellow. It does not establish a postdoctoral appointment or start date.
Research affiliation: Ky Lab, Perelman School of Medicine; postdoctoral and clinical fellows section
Postdoctoral and Clinical Fellows ... Javier Sierra Pagan ... Cardiovascular Disease Fellow
- [8]External Fellowships | University of Minnesota MSTP
1 source claim · 1 journey details · Reviewed Sep 5, 2026
NIH/NHLBI F30 research fellowship: 2020 to 2023. Minnesota lists Sierra-Pagán's NHLBI F30 award, HL152561, for work on mechanisms governing vasculogenesis.
Research award: NIH/NHLBI F30 HL152561, Mechanisms that govern vasculogenesis
2020 to 2023
Javier Sierra-Pagán | 2020-2023 | (NIH/NHLBI F30 HL152561) | Mechanisms that govern vasculogenesis
- [9]MSTP Graduate Residency Match Information | University of Minnesota Medical School
1 source claim · 5 journey details · Reviewed Sep 5, 2026
MD-PhD program: Enrolled beginning Jul 2016; completion endpoint unknown. The self-reported ORCID entry identifies one University of Minnesota MD-PhD program beginning in July 2016. The dissertation record supplies a June 2022 PhD completion point, and Minnesota's 2024 match list supplies a later residency-match observation. The stale ORCID 'present' endpoint is not used as a completion date.
Matched to Penn Internal Medicine Physician Scientist Training Program: 2024 match
Internal Medicine Physician Scientist Training Program: Matched in 2024; attendance dates unknown. Minnesota's 2024 match list names Penn Internal Medicine PSTP, and Penn later names its own hospital as Sierra-Pagan's residency institution. The match year is a point observation, not a residency start date.
Sierra-Pagan reports beginning an MD-PhD program at the University of Minnesota in July 2016. ORCID's old 'present' endpoint does not establish when the program ended, while Minnesota separately dates the PhD dissertation to June 2022 and the residency match to 2024.
The available sources do not establish pre-medical education, the MD conferral date, or exact residency dates.
Residency: Internal Medicine Physician Scientist Training Program, University of Pennsylvania
2024 ... Javier Sierra Pagan: Internal Medicine (PSTP), Univ of Pennsylvania
